

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

APPOINTMENT OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY

APPOINTMENT OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Tong Shaojing (童少靖) (“**Mr. Tong**”) has been appointed as the chief financial officer and a joint company secretary of the Company with effect from September 28, 2023. Ms. Tam Pak Yu, Vivien (譚栢如) (“**Ms. Tam**”) will continue to serve as the other joint company secretary of the Company.

The biographical details of Mr. Tong are set out below:

Mr. Tong has more than 21 years of experience in investment banking, focusing on the global healthcare sector, and has acquired a deep understanding of both the U.S. and Asian healthcare markets. From June 2019 to December 2022, he served as the chief financial officer of InnoCare Pharma Limited (諾誠健華醫藥有限公司), a company listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 9969) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688428). From July 2013 to May 2019, he worked at UBS AG with his last position being an executive director in the investment banking research department. From May 2008 to May 2013, he worked at Bank of America Merrill Lynch with his last position being a director in global research. From June 2001 to April 2008, he worked as an equity analyst in multinational pharmaceutical companies equity research at Mehta Partners.

Mr. Tong obtained his bachelor of science degree in material science and engineering from the University of Science and Technology of China (中國科學技術大學) in the PRC in July 1993. He further obtained his master's degree in chemistry from the University of Pittsburgh in the United States in August 1996, and his master of business administration degree in finance from New York University in the United States in May 2001.

The biographical details of Ms. Tam are set out below:

Ms. Tam was appointed as a joint company secretary of the Company on May 11, 2020. Ms. Tam has over seven years of experience in the corporate secretarial field, and is currently serving as a manager of SWCS Corporate Services Group (Hong Kong) Limited (方圓企業服務集團(香港)有限公司), a professional services provider specializing in corporate services. Ms. Tam has been admitted as an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute of the United Kingdom since 2018.

Ms. Tam obtained her bachelor's degree in China Studies from Hong Kong Baptist University (香港浸會大學) in 2014. She further obtained her master's degree in professional accounting and corporate governance from City University of Hong Kong (香港城市大學) in 2017.

The Board would like to express its warmest welcome to Mr. Tong on his new positions in the Company.

Save as disclosed herein, the Board is not aware of any other matters in relation to the appointment of Mr. Tong that need to be brought to the attention of the shareholders of the Company or the Stock Exchange or any other information that needs to be disclosed pursuant to the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rules 3.28 and 8.17 of the Listing Rules, an issuer must appoint a company secretary who, by virtue of his/her academic or professional qualifications or relevant experience, is, in the opinion of the Stock Exchange, capable of discharging the functions of the company secretary.

Note 1 to Rule 3.28 of the Listing Rules provides that the Stock Exchange considers the following academic or professional qualifications to be acceptable: (a) a member of The Hong Kong Chartered Governance Institute; (b) a solicitor or barrister as defined in the

Legal Practitioners Ordinance (Chapter 159 of the Laws of Hong Kong); and (c) a certified public accountant (as defined in the Professional Accountants Ordinance (Chapter 50 of the Laws of Hong Kong)) (collectively, the “**Acceptable Qualifications**”).

Note 2 to Rule 3.28 of the Listing Rules provides that the Stock Exchange considers the following factors in assessing the “relevant experience” of the individual: (a) length of employment with the issuer and other issuers and the roles he/she played; (b) familiarity with the Listing Rules and other relevant law and regulations including the Securities and Futures Ordinance, the Companies Ordinance, the Companies (Winding Up and Miscellaneous Provisions) Ordinance and the Code on Takeovers and Mergers and Share Buy-backs; (c) relevant training taken and/or to be taken in addition to the minimum requirement under Rule 3.29 of the Listing Rules; and (d) professional qualifications in other jurisdictions (collectively, the “**Relevant Experience**”).

With his previous experience of working at another biopharmaceutical company listed on the Stock Exchange prior to his joining of the Company, Mr. Tong has familiarized himself with the board and corporate management matters of a listed company in Hong Kong. Also, Mr. Tong will maintain a close nexus with the Board and work closely with the Board and senior management of the Company and brief them on the board and corporate management matters of the Company from time to time. Having regard to Mr. Tong’s past working experience and background as well as the close working relationship with the management of Company, the directors of the Company are of the view that he has a thorough understanding of, among other things, the corporate development, business strategies, internal operations and management of the Group. Therefore, the Board is of the view that Mr. Tong will be the suitable candidate to perform the duties as a joint company secretary with his skills and competence, and to take the necessary actions for the Company in an effective and efficient manner.

However, since Mr. Tong does not possess the Acceptable Qualifications required under Note 1 to Rule 3.28 of the Listing Rules, and he does not have the Relevant Experience required by Note 2 to Rule 3.28 of the Listing Rules, he has not fully satisfied the requirements under Rule 3.28 of the Listing Rules.

As such, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules (the “**Waiver**”) for three years from the date of appointment of Mr. Tong as a joint company secretary of the Company (the “**Waiver Period**”). Ms. Tam, being an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute of the United Kingdom, meets the requirements under Note

1 to Rule 3.28 of the Listing Rules, and will work closely with and provide assistance to Mr. Tong in discharging his duties and responsibilities as a company secretary of the Company during the Waiver Period.

The Waiver was granted on the conditions that: (i) Mr. Tong will be assisted by Ms. Tam during the Waiver Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Pursuant to the Waiver, the Company should announce the reasons, details and conditions of the Waiver, and the qualification and experience of both Mr. Tong and Ms. Tam. The publication of this announcement aims to satisfy this requirement.

Before the end of the Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Mr. Tong, having had the benefit of Ms. Tam's assistance during the Waiver Period, has attained the Relevant Experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People's Republic of China
September 28, 2023

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive directors.

* *For identification purpose only*